US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

7.81

-0.0400-0.51%

Post-market: 7.850.0400+0.51%18:09 EST

Volume:223.26K

Turnover:1.75M

Market Cap:2.62B

PE:183.16

High:7.96

Open:7.96

Low:7.74

Close:7.85

52wk High:30.36

52wk Low:7.72

Shares:335.00M

Float Shares:272.00M

Volume Ratio:0.91

T/O Rate:0.08%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0426

EPS(LYR):0.0933

ROE:3.14%

ROA:2.08%

PB:6.20

PE(LYR):83.74

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Does Telix (ASX:TLX) And Varian’s PSMA-PET Tie-Up Redefine Its Radiotherapy Moat?

Simply Wall St.

Telix Pharmaceuticals Poised for 'Solid' Q4 Revenue Growth, Jefferies Says

MT Newswires Live

Telix Pharmaceuticals (ASX:TLX) Valuation Check as ProstACT Global Phase 3 Trial Progresses to Part 2

Simply Wall St.

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TLX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":7.81,"timestamp":1766091600000,"preClose":7.85,"halted":0,"volume":223259,"hourTrading":{"tag":"盘后","latestPrice":7.85,"preClose":7.81,"latestTime":"18:09 EST","volume":1054,"amount":8273.74,"timestamp":1766099372097},"delay":0,"floatShares":272000000,"shares":335000000,"eps":0.04264,"marketStatus":"Closed","change":-0.04,"latestTime":"12-18 16:00:00 EST","open":7.96,"high":7.96,"low":7.74,"amount":1752688.8408106,"amplitude":0.028025,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.04264,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":7.85,"preHourTrading":{"tag":"盘前","latestPrice":7.99,"preClose":7.85,"latestTime":"09:27 EST","volume":3830,"amount":30089.76688,"timestamp":1766068040011},"postHourTrading":{"tag":"盘后","latestPrice":7.85,"preClose":7.81,"latestTime":"18:09 EST","volume":1054,"amount":8273.74,"timestamp":1766099372097},"volumeRatio":0.911615},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.08%","roe":"3.14%","lyrEps":0.093266,"volumeRatio":0.911615,"shares":335000000,"dividePrice":0,"high":7.96,"amplitude":0.028025,"preClose":7.85,"low":7.74,"week52Low":7.7198,"pbRate":"6.20","psRate":"3.94","week52High":30.36,"institutionHeld":0,"latestPrice":7.81,"eps":0.04264,"divideRate":0,"volume":223259,"delay":0,"ttmEps":0.04264,"open":7.96,"prevYearClose":15.4,"prevWeekClose":9.03,"prevMonthClose":9.95,"prevQuarterClose":9.57,"fiveDayClose":9.37,"twentyDayClose":9.04,"sixtyDayClose":10.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758171600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2025-12-17","current":183.161351,"percent":0.699634,"low":113.06761,"twenty":165.913838,"median":180.788993,"eighty":295.177019,"high":383.853933,"avg":212.569301,"sd":66.933096,"marketCap":2627604982.47},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-17","current":242.301839,"twenty":165.913838,"median":180.788993,"eighty":295.177019,"marketCap":2627604982.47}],"updateTime":1766112767423},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2590331577","title":"Does Telix (ASX:TLX) And Varian’s PSMA-PET Tie-Up Redefine Its Radiotherapy Moat?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590331577","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590331577?lang=en_us&edition=fundamental","pubTime":"2025-12-12 12:40","pubTimestamp":1765514409,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced a clinical collaboration with Varian, a Siemens Healthineers company, to combine its theranostic radiopharmaceuticals with external beam radiation therapy, initially focusing on PSMA-PET imaging in prostate cancer. \nThis tie-up could broaden the role of nuclear medicine in radiation oncology by using Telix’s Gozellix and Illuccix to sharpen patient selection and treatment planning. \nNext, we’ll examine how this Varian collaboration around...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-telix-asxtlx-and-varians-psma-pet-tie-up-redefine-its-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-telix-asxtlx-and-varians-psma-pet-tie-up-redefine-its-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TLX","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2590541735","title":"Telix Pharmaceuticals Poised for 'Solid' Q4 Revenue Growth, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541735","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541735?lang=en_us&edition=fundamental","pubTime":"2025-12-12 05:42","pubTimestamp":1765489325,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  is set for a \"solid\" revenue growth in the fourth quarter of the year, as the median reimbursement for its new prostate cancer imaging agent, Gozellix, by the US Centers for Medicare & Medicaid Services  is likely to be above $7,000 per dose, according to a Thursday note by Jefferies.The company earlier received approval from the CMS for the start of transitional pass-through reimbursement for Gozellix in the fourth quarter.TLX also said it expects higher fourth quarter prostate-specific membrane antigen positron emission tomography  revenue than the previous quarter due to Gozellix's impact, Jefferies noted.Jefferies expects the company's full-year US PSMA PET sales volume to be about 120,500.The investment firm reaffirmed a buy rating on Telix with a AU$27.10 price target.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"gpt_icon":0},{"id":"2590598517","title":"Telix Pharmaceuticals (ASX:TLX) Valuation Check as ProstACT Global Phase 3 Trial Progresses to Part 2","url":"https://stock-news.laohu8.com/highlight/detail?id=2590598517","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590598517?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:27","pubTimestamp":1765420032,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has dosed the first patient in Part 2 of its ProstACT Global Phase 3 trial for TLX591 in advanced prostate cancer, a key step that can reshape future value expectations.\nSee our latest analysis for Telix Pharmaceuticals.\nThis milestone comes after a tough stretch for investors, with the share price down sharply on a year to date basis even as the 3-year total shareholder return of 97.18 percent still points to strong long term wealth creation. This suggests...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-valuation-check-as-prostact-glo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-valuation-check-as-prostact-glo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK7067","TLX","BK4139","DCF"],"gpt_icon":0},{"id":"2589060328","title":"ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2589060328","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589060328?lang=en_us&edition=fundamental","pubTime":"2025-12-08 06:08","pubTimestamp":1765145280,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ --Telix Pharmaceuticals Limited  today announces that the first patienthas been dosed in Part 2  of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591  in patients with metastatic castration resistant prostate cancer . The patient was dosed at the Australian Prostate Centre  in Melbourne, Australia.ProstACT Global is the first Phase 3 trial to combine aPSMA[1]-targeted radio antibody-drug conjugate  therapy administered together with Standard of Care  versus SOC alone. Part 2 of ProstACT Global will enroll approximately 490 patients and is currently recruiting patients in Australia, New Zealand and Canada.As previously agreed with FDA and disclosed to the market, Telix will submit Part 1 data to the United States  Food and Drug Administration  to enable clearance to expand Part 2 of the trial to U.S. sites. A public disclosure of preliminary results from Part 1 of the study will","market":"sg","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prostact-global-phase-3-update-first-patient-dosed-in-randomized-treatment-expansion-part-1-readout-plans-confirmed-302634831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEC.AU","LU0882574139.USD","EMA","ASX.AU","LU0053666078.USD","LU1066053197.SGD","BK7129","EMA.AU","LU0170899867.USD","LU1935042991.SGD","LU1935043023.USD","XJO.AU","CTA","APC.AU","LU2237443622.USD","BK4139","APC","LU2236285917.USD","LU2237443549.SGD","LU1066051225.USD","RLT.AU","LU2456880835.USD","LU1935042488.USD","LU2237443382.USD","XAO.AU","BK4526","LU0786609619.USD","BK4543","XKO.AU","ASX","LU0314104364.USD","BK7095","LU1778281490.HKD","TLX.AU","LU2083900584.USD","LU0077335932.USD","BK4141","BK7067","LU0149725797.USD","LU1366192091.USD","TLX","LU2237443978.SGD","LU1066051498.USD","LU1674673691.USD","LU1935043536.SGD","LU2420271590.USD","LU1496350171.SGD","LU1718418525.SGD","BK7142","LU1066051811.HKD"],"gpt_icon":0}],"pageSize":4,"totalPage":18,"pageCount":1,"totalSize":72,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TLX\",params:#limit:6,delay:false,,,undefined,":[]}}